Article

LCA Joins Efforts to Protect Patient Access to Treatments

The Lung Cancer Alliance has joined a growing list of patient advocacy organizations in supporting the American Cancer Society Cancer Action Network's advertising campaign urging the Trump administration not to limit access to lifesavings medications under Medicare.

The Lung Cancer Alliance has joined a growing list of patient advocacy organizations in supporting the American Cancer Society Cancer Action Network's advertising campaign urging the Trump administration not to limit access to lifesavings medications under Medicare. They Six Protected Classes at stake include therapies for epilepsy, mental illness, cancer, HIV, and organ transplants.

The ads will be featured in The Washington Post, The New york Times, The Hill, Roll Call, and Politico. Read the full press release.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
David Awad, PharmD, BCOP
Andrew Kuykendall, MD, Moffitt Cancer Center
Merrill H. Stewart, MD
Dr Margrit Wiesendanger
David Awad, PharmD, BCOP
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Dr Margrit Wiesendanger
Ibrahim Aldoss, MD, associate professor, City of Hope
Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami Cancer Institute of Baptist Health South Florida
Cathy Eng, MD, FACP, FASCO
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo